Written based on 14 research studies on PubMed, searched on 2026. nov. 12..
The claim
Posts say that mRNA vaccines can help treat melanoma, a type of skin cancer.
Where research stands
We found 46 published papers on mRNA vaccine and melanoma in PubMed. They were published between 2018 and 2026. 1 of them is a study in people. The papers do not say how many people took part. None of them compared people who got it with a group that did not. 22 were studies in animals, and 1 was only in cells in the lab. 9 papers are reviews that sum up other studies.
- 1In people
- 22In animals
- 1Only in the lab
What the studies found
Trials in people
We found one study in people. It was a first small test, mainly to check safety. [1] The patients had advanced melanoma that surgery could not remove. [1] Some patients had lasting responses, with the vaccine alone or with another drug. [1] The study had no comparison group, so it cannot show the vaccine caused the responses. [1]
Other studies in people
A 2026 comment says a vaccine from Merck and Moderna cut the risk of melanoma coming back. [2] It says why this happens is still unclear. [2] A study of 4,407 patients linked COVID-19 vaccination to better survival in melanoma and lung cancer. [3] That study was about COVID-19 vaccines, not melanoma vaccines, and it does not prove cause. [3]
Reviews
A review describes a test where a personal vaccine was added to a common immunotherapy drug. [4] Patients had melanoma at high risk of coming back after surgery removed the cancer. [4] After 18 months, 79 in 100 with the vaccine were free of melanoma, vs 62 in 100 without it. [4] The result was close to chance, so it is not firm proof. [4] Reviews say big problems remain, like getting the vaccine into the right cells. [6][7]
In animals
In mice with melanoma, mRNA vaccines slowed tumour growth. [9][10][11] One vaccine with another drug suppressed tumours by 93.5%, say the authors. [10] Results in animals do not always hold in people.
In the lab
A lab study found a carrier that moved mRNA into immune cells and switched on an immune signal. [14] The authors say it also worked against tumours in mice. [14]
Verdict
The one small test in people had lasting responses, but no comparison group. [1] A larger test hinted at benefit, but its result was close to chance. [4] Mouse results are promising, but this is not yet firm proof, so the claim is partly true. [9][10][11][4]
Partly true means: people did well, but no fair test with a comparison group has shown it yet. Or only part of the claim holds. How we rate claims
What this means for you: A study in people is not proof that it helps you. Do not stop or change your medicines because of it. Ask your doctor before you start taking it.
Sources
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.2020 · Nature · Study in people
- Milestone cancer vaccine success leaves hard questions unanswered.2026 · Science · Other paper
- Validation of "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade" in an independent cohort of 4,407 patients.2026 · Cancer Lett · Other paper
- Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies.2025 · Cells · Review
- How Deeply Can mRNA Vaccines Affect the Responsiveness to Immune Checkpoint Inhibitors Through Changes in the Tumor Microenvironment? Evidence from Melanoma.2026 · Cells · Review
- mRNA Vaccines in Melanoma Immunotherapy-A Narrative Review.2026 · Cells · Review
- Individualized mRNA Vaccines in Melanoma-Where Do We Stand?2025 · Vaccines (Basel) · Review
- Advances in mRNA-Based Melanoma Vaccines: A Narrative Review of Lipid Nanoparticle and Dendritic Cell Delivery Platforms.2026 · Cells · Review
- NanoReady: A ready-made DC-selective delivery platform for personalized mRNA cancer vaccines with strong NHP immunogenicity.2026 · J Control Release · In animals
- Enhanced mRNA vaccine combined with immune checkpoint blockade efficiently suppresses tumor growth and metastasis.2026 · J Nanobiotechnology · In animals
- A Stable RNA Vaccine Against the Regulatory Peptide Adrenomedullin Reduces Angiogenesis and Tumor Burden in a Subcutaneous Melanoma Model Without Inducing an Immunosuppressive Tumor Microenvironment.2025 · Int J Mol Sci · In animals
- An engineered linear cap-independent mRNA vaccine with intrinsic adjuvanticity induces potent anti-tumor immunity in mice.2026 · Nat Commun · In animals
- Zn(II)-adjuvanted imidazole-based lipid nanoparticles for potent spleen-targeted mRNA delivery and enhanced immune activation.2026 · J Control Release · In animals
- Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling.2021 · Proc Natl Acad Sci U S A · In the lab
